Skip to main content

AEON Biopharma, Inc.

corporate_fare Company Profile

AEON Biopharma, Inc.

AEON·NYSE·Life Sciences·CIK 0001837607

AEON Biopharma, Inc. is a biopharmaceutical company focused on developing ABP-450, its proprietary botulinum toxin complex, as a biosimilar to Botox® (onabotulinumtoxinA) for therapeutic indications, with the goal of achieving full-label United States market entry for debilitating medical conditions. The company's strategy is to pursue regulatory approval in the United States through a BLA under Section 351(k) of the Public Health Service Act (a "Section 351(k) BLA"). AEON holds exclusive development and commercialization rights for ABP-450 in therapeutic indications across the United States, Canada, the European Union, the United Kingdom, and certain other international territories. AEON became a public company through a business combination. On December 12, 2022, AEON Biopharma Sub, Inc. (formerly known as AEON Biopharma, Inc., or "Old AEON") and Priveterra Merger Sub, Inc., a wholly owned subsidiary of Priveterra Acquisition Corp. — a special purpose acquisition company formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more target businesses — entered into a Business Combination and Merger Agreement dated December 12, 2022, amended April 27, 2023. On July 21, 2023, the parties consummated the transactions contemplated by the agreement. On the Closing Date, Old AEON merged with Priveterra Merger Sub, Inc., with Old AEON surviving as a wholly owned subsidiary of the Company; the Company changed its name from "Priveterra Acquisition Corp." to "AEON Biopharma, Inc."; and Old AEON changed its name to AEON Biopharma Sub, Inc. Following the Closing, the Company's common stock was listed on the NYSE American under the symbol "AEON" and commenced trading on July 24, 2023.

AEON Biopharma, Inc. (NYSE:AEON) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for AEON at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 5 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for AEON spans 10-Q, 8-K, SCHEDULE 13D/A, 424B3.

Recent high-impact activity:

  • AEON 10-Q: $2.5M Q3 Profit Is Non-Cash; Going Concern and $0.25 Delisting Rule Loom
  • AEON Posts Q3 Net Income of $2.5M on Warrant Remeasurement; Cash Runway to Q2 2027
  • Daewoong Exercises Pre-Funded Warrants, Stake Rises to 30.6% of AEON
  • AEON Cuts Two-Year Warrant Strike to $0.20, Expects $6.2M From Exercises Before Nov 16 Expiry
  • AEON Cuts Warrant Strike to $0.20, Expects ~$6.2M From Induced Exercises

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$39.22M
Diluted EPS
-$3.95
Op. Cash Flow
-$17.31M
Operating Income
-$12.8M
Cash & Equivalents
$3.01M
Debt / Equity
0.00×
Shares Outstanding
12.11M sh
Source: 10-K · filed 2026-03-30 · accession 0001837607-26-000019

Short Interest & Short Volume

6.40 days to cover

FINRA reported short interest of 2,661,529 shares in AEON as of the October 30, 2026 settlement, a 18.1% decrease from the prior period — about 6.4 days to cover at its recent average daily volume. On November 20, 2026, 59.1% of AEON volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,661,529 shares as of October 30, 2026
Change vs prior period▼ 18.1%
Days to cover6.40 at avg daily volume of 415,775
Daily short volume (FINRA facilities)59.1% of 399,191 shares on November 20, 2026
5-day average short volume56.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for AEON, detected from its recent SEC filings · based on capital-structure filings through 2026-11-03.

1 recent capital raise

Warrant Strike Cut to $0.20 · About $6.2M Expected From Exercises

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$0.124 +0.81% today
52-week range · as of 2026-11-16 $0.124 – $1.45
Market cap
$10.35M
Volume
1.2M (1.0× avg)
3-mo avg 1.1M
Live data · 2026-11-22 12:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AEON - Latest Insights

AEON
Nov 16, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.141
Real-time Price: $0.124 info
Change: -$0.017 (-12%) info
Market Cap: $10.347M info
AEON
Nov 16, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.141
Real-time Price: $0.124 info
Change: -$0.017 (-12%) info
Market Cap: $10.347M info
AEON
Nov 10, 2026, 12:12 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.172
Real-time Price: $0.124 info
Change: -$0.048 (-28%) info
Market Cap: $10.347M info
AEON
Nov 03, 2026, 8:43 AM EST
Filing Type: 424B3
Importance Score:
7
Price at Filing: $0.2797
Real-time Price: $0.124 info
Change: -$0.1557 (-56%) info
Market Cap: $10.347M info
AEON
Nov 03, 2026, 8:42 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2797
Real-time Price: $0.124 info
Change: -$0.1557 (-56%) info
Market Cap: $10.347M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets